Theraclone Sciences, Inc. - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 49

Theraclone Sciences, Inc. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Theraclone Sciences, Inc. - Product Pipeline Review - 2012” provides data on the Theraclone Sciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Theraclone Sciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Theraclone Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Theraclone Sciences, Inc. - Brief Theraclone Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Theraclone Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Theraclone Sciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Theraclone Sciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Theraclone Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Theraclone Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Theraclone Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Theraclone Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Theraclone Sciences, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Theraclone Sciences, Inc.; Theraclone Sciences, Inc. - Key Therapeutics; Theraclone Sciences, Inc. - Pipeline Overview and Promising Molecules; Theraclone Sciences, Inc. - News; Theraclone Sciences, Inc. - Latest Updates; Theraclone Sciences, Inc. - Pipeline; Theraclone Sciences, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Theraclone Sciences, Inc. Snapshot
Theraclone Sciences, Inc. Overview
Key Information
Key Facts
Theraclone Sciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Theraclone Sciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Theraclone Sciences, Inc. – Pipeline Products Glance
Theraclone Sciences, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Theraclone Sciences, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Theraclone Sciences, Inc. – Drug Profiles
Anti-IL-12/23 p40 Human Antibodies
Product Description
Mechanism of Action
R&D Progress
Anti-IL-23 Human Antibodies
Product Description
Mechanism of Action
R&D Progress
GM-CSF
Product Description
Mechanism of Action
R&D Progress
HIV Antibody Program
Product Description
Mechanism of Action
R&D Progress
Interferon-Alpha
Product Description
Mechanism of Action
R&D Progress
TCN-032
Product Description
Mechanism of Action
R&D Progress
TCN-202
Product Description
Mechanism of Action
R&D Progress
Theraclone Sciences, Inc. – Pipeline Analysis
Theraclone Sciences, Inc. – Pipeline Products by Therapeutic Class
Theraclone Sciences, Inc. – Pipeline Products By Target
Theraclone Sciences, Inc. – Pipeline Products by Route of Administration
Theraclone Sciences, Inc. – Pipeline Products By Mechanism of Action
Theraclone Sciences, Inc. – Recent Pipeline Updates
Theraclone Sciences, Inc. – Locations And Subsidiaries
Head Office
Theraclone Sciences, Inc., Recent Developments
Theraclone Sciences, Inc.- Press Release
May 15, 2012: Theraclone Announces Positive Top-line Phase I Data Of TCN-032 For Treatment Of Influenza A
Sep 23, 2009: Lilly Highlights Transformation Strategy For Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Sep 03, 2009: Findings Reveal An Achilles Heel On The Virus For AIDS Vaccine Researchers To Exploit
Jul 06, 2009: IAVI And Theraclone Expand HIV Antibody Discovery Collaboration
Mar 30, 2009: Spaltudaq Corp. Announces Identification of Broadly and Potently Neutralizing Human HIV Antibodies and Change of Company Name to Theraclone Sciences, Inc.
Financial Deals Landscape
Theraclone Sciences, Inc., Deals Summary
Theraclone Sciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Theraclone Sciences Secures Additional $1 Million In Extended Series B Financing
Theraclone Sciences Secures An Additional $1.5 Million In Series B Venture Financing
Spaltudaq Secures $29 Million In Series B Financing
Theraclone Sciences Secures $1.2 Million In Series A Financing
Partnerships
Theraclone Sciences Enters Into Joint Venture With VLST To Form V-Gene
Theraclone Sciences Enters Into Co-Development Agreement With Pfizer
Theraclone Sciences Enters Into Co-Development With Zenyaku Kogyo
Theraclone Sciences Expand Its Collaboration With International AIDS Vaccine Initiative
Licensing Agreements
Zenyaku Kogyo Enters Into License Agreement With Theraclone
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Theraclone Sciences, Inc., Key Information
Theraclone Sciences, Inc., Key Facts
Theraclone Sciences, Inc. – Pipeline by Indication, 2012
Theraclone Sciences, Inc. – Pipeline by Stage of Development, 2012
Theraclone Sciences, Inc. – Monotherapy Products in Pipeline, 2012
Theraclone Sciences, Inc. – Phase I, 2012
Theraclone Sciences, Inc. – Pre-Clinical, 2012
Theraclone Sciences, Inc. – Discovery, 2012
Theraclone Sciences, Inc. – Pipeline By Therapeutic Class, 2012
Theraclone Sciences, Inc. - Pipeline By Target, 2012
Theraclone Sciences, Inc. – Pipeline By Route of Administration, 2012
Theraclone Sciences, Inc. – Pipeline Products By Mechanism of Action, 2012
Theraclone Sciences, Inc. – Recent Pipeline Updates, 2012
Theraclone Sciences, Inc., Deals Summary
Theraclone Sciences Secures Additional $1 Million In Extended Series B Financing
Theraclone Sciences Secures An Additional $1.5 Million In Series B Venture Financing
Spaltudaq Secures $29 Million In Series B Financing
Theraclone Sciences Secures $1.2 Million In Series A Financing
Theraclone Sciences Enters Into Joint Venture With VLST To Form V-Gene
Theraclone Sciences Enters Into Co-Development Agreement With Pfizer
Theraclone Sciences Enters Into Co-Development With Zenyaku Kogyo
Theraclone Sciences Expand Its Collaboration With International AIDS Vaccine Initiative
Zenyaku Kogyo Enters Into License Agreement With Theraclone

List of Figures
Theraclone Sciences, Inc. – Pipeline by Indication, 2012
Theraclone Sciences, Inc. – Pipeline by Stage of Development, 2012
Theraclone Sciences, Inc. – Monotherapy Products in Pipeline, 2012
Theraclone Sciences, Inc. – Pipeline By Therapeutic Class, 2012
Theraclone Sciences, Inc. - Pipeline By Target, 2012
Theraclone Sciences, Inc. - Pipeline Products By Mechanism of Action, 2012

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Ixia - Company Analysis
• Amazon - Point of Realization in 2013?
• Analysis of Google Inc
• Insight into Samsung Electronics' Notebook PC Business Model